XML 38 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting and Disaggregation of Relevant Expense Captions (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents information about reported segment revenues, segment profit, and significant segment expenses.
Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2025202420252024
Revenues:
INGREZZA net product sales$686.6 $612.9 $1,856.2 $1,698.4 
CRENESSITY net product sales98.1 — 165.8 — 
Other revenues (1)
10.2 9.2 33.0 29.2 
Total revenues794.9 622.1 2,055.0 1,727.6 
Less:
Cost of revenues14.0 8.0 34.5 24.7 
Research and development:
External research and development 141.8 82.9 370.3 250.4 
Payroll and benefits74.6 55.4 221.8 167.9 
Milestones1.0 38.8 61.5 71.4 
Other research and development (2)
32.6 17.9 103.9 55.8 
Total research and development250.0 195.0 757.5 545.5 
Acquired in-process research and development0.3 1.0 0.4 9.5 
Selling, general, and administrative291.6 234.3 854.4 719.4 
Unrealized (gain) loss on equity investments
(30.6)16.9 6.7 35.2 
Charges associated with convertible senior notes— — — 138.4 
Interest income and other, net
(22.2)(23.4)(64.5)(68.5)
Provision for income taxes
82.3 60.5 141.1 85.2 
Net income
$209.5 $129.8 $324.9 $238.2 
_________________________
(1) Other revenues primarily consist of net product sales for ALKINDI and EFMODY and royalties earned on AbbVie net sales of elagolix and MTPC net sales of valbenazine.
(2) Other research and development consists of indirect costs incurred for the benefit of multiple research and development programs, including facility-based expenses (such as rent expense) and other overhead allocations.